» Articles » PMID: 15753841

Human Amniotic Mesenchymal Cells Have Some Characteristics of Cardiomyocytes

Overview
Journal Transplantation
Specialty General Surgery
Date 2005 Mar 9
PMID 15753841
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cellular cardiomyoplasty (CCM) is a major method for the treatment of heart failure because adult cardiomyocytes do not regenerate after ischemic injury, which results in heart failure. There is a great deal of interest in finding suitable new cell sources for use in CCM. Here, we report that human amniotic mesenchymal cells (hAMC), which are multipotent cells derived from fetal mesoderm, may be a suitable cell source for CCM.

Methods: Freshly isolated hAMC were examined to detect the expression of cardiac-specific genes by reverse-transcription polymerase chain reaction and immunocytochemistry. hAMC were cocultivated with neonatal rat heart explants and transplanted into myocardial infarcts in the rat heart.

Results: hAMC expressed cardiac-specific transcription factor GATA4, cardiac-specific genes, such as myosin light chain (MLC)-2a, MLC-2v, cTnI, and cTnT, and the alpha-subunits of the cardiac-specific L-type calcium channel (alpha1c) and the transient outward potassium channel (Kv4.3). After stimulation with basic fibroblast growth factor (bFGF) or activin A, hAMC expressed Nkx2.5, a specific transcription factor for the cardiomyocyte and cardiac-specific marker atrial natriuretic peptide. In addition, the cardiac-specific gene alpha-myosin heavy chain was detected after treatment with activin A. Coculture experiments confirmed that hAMC were able to both integrate into cardiac tissues and differentiate into cardiomyocyte-like cells. After transplantation into the myocardial infarcts in rat hearts, hAMC survived in the scar tissue for at least 2 months and differentiated into cardiomyocyte-like cells.

Conclusion: The results of the present study suggest that hAMC possess some characteristics of cardiomyocytes.

Citing Articles

Role of Mesenchymal Stem/Stromal Cells in Modulating Ischemia/Reperfusion Injury: Current State of the Art and Future Perspectives.

Miceli V, Bulati M, Gallo A, Iannolo G, Busa R, Conaldi P Biomedicines. 2023; 11(3).

PMID: 36979668 PMC: 10045387. DOI: 10.3390/biomedicines11030689.


Plumping up a Cushion of Human Biowaste in Regenerative Medicine: Novel Insights into a State-of-the-Art Reserve Arsenal.

Najafi-Ghalehlou N, Feizkhah A, Mobayen M, Pourmohammadi-Bejarpasi Z, Shekarchi S, Roushandeh A Stem Cell Rev Rep. 2022; 18(8):2709-2739.

PMID: 35505177 PMC: 9064122. DOI: 10.1007/s12015-022-10383-3.


Therapeutic Potential of Human Fetal Mesenchymal Stem Cells in Musculoskeletal Disorders: A Narrative Review.

Song I, Rim J, Lee J, Jang I, Jung B, Kim K Int J Mol Sci. 2022; 23(3).

PMID: 35163361 PMC: 8835918. DOI: 10.3390/ijms23031439.


Applications of the amniotic membrane in tissue engineering and regeneration: the hundred-year challenge.

Elkhenany H, El-Derby A, Elkodous M, Salah R, Lotfy A, El-Badri N Stem Cell Res Ther. 2022; 13(1):8.

PMID: 35012669 PMC: 8744057. DOI: 10.1186/s13287-021-02684-0.


Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues-Origins, Characteristics, Signaling Pathways, and Clinical Trials.

Kulus M, Sibiak R, Stefanska K, Zdun M, Wieczorkiewicz M, Piotrowska-Kempisty H Cells. 2021; 10(12).

PMID: 34943786 PMC: 8699543. DOI: 10.3390/cells10123278.